Altium Capital Management LLC Sells 43,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Altium Capital Management LLC reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 25.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,000 shares of the biotechnology company’s stock after selling 43,000 shares during the quarter. Sarepta Therapeutics makes up approximately 4.4% of Altium Capital Management LLC’s portfolio, making the stock its 4th biggest position. Altium Capital Management LLC owned 0.13% of Sarepta Therapeutics worth $15,442,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Manchester Capital Management LLC raised its position in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 156 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter worth about $36,000. Steward Partners Investment Advisory LLC boosted its holdings in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 216 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SRPT has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft decreased their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Needham & Company LLC reduced their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a research note on Thursday, April 3rd. Morgan Stanley decreased their price target on Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating on the stock in a research note on Friday, April 11th. Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a report on Thursday, March 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $161.83.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $53.94 on Thursday. The stock’s 50 day simple moving average is $84.51 and its 200 day simple moving average is $108.84. Sarepta Therapeutics, Inc. has a 12-month low of $48.01 and a 12-month high of $173.25. The firm has a market cap of $5.23 billion, a P/E ratio of 43.15 and a beta of 0.93. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.